Development of a new treatment method using a combination of lysophosphatidic acid and radiotherapy

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K15807
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Osaka University
• Principal Investigator: Eino Daisuke 大阪大学, 大学院医学系研究科, 招へい教員 (70726520)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 腫瘍血管正常化 / 癌 / LPA / 血管新生 / 放射線治療

Outline of Final Research Achievements

LPA was administered to mice with subcutaneous LLC tumors and mice with GL261 brain tumors to examine whether it enhanced the antitumor effect of X-ray irradiation, but no significant changes were observed between the groups. Drug delivery in tumors treated with LPA in the GL261 brain tumor model were measured using PET-CT. FDG and FBPA (amino acid) were used as tracers. There were no significant increase in tracer uptake due to LPA. Tumor sections with X-ray irradiation were stained with anti-CD31 antibody to examine morphological changes in tumor blood vessels. No obvious changes were observed in blood vessel density or vasculature.

Free Research Field

放射線治療

Academic Significance and Societal Importance of the Research Achievements

悪性腫瘍内の異常な新生血管をLPAによって正常化することで放射線治療の効果を増強させることができるかどうかの研究を行った。今回行った一連の研究において、LPAによる放射線治療増強は確認できなかったが、今までの研究からは抗がん剤、免疫療法の増強効果は示している。臨床のがん治療は抗がん剤、放射線治療、手術、免疫療法など様々なモダリティを用いて治療が行われており、LPAは各治療モダリティを結びつけ、互いに増強し合い、治療困難な癌腫の治療成績向上に貢献すると考えている。